Designing tumor microenvironment (TME)-specific active nanoparticles with minimum side effects for synergistic cancer therapy has become a hot topic in the recent decades. Aiming at further enhancing the therapeutic efficacy, an in situ-induced mitochondrial dysfunction is a very promising strategy. To achieve these goals, a nano-sono-chemodynamic agent denoted as TPP-Cu@HMS, which integrated hematoporphyrin monomethyl ether (HMME), mPEG-NHS, triphenylphosphonium (TPP)-decorated mesoporous silica (MS) and coordinatively bound Cu 2+ ions for mitochondria-specific sonodynamicchemodynamic therapy (SDT-CDT) of cancer, was designed. Upon the ultrasound (US) treatment, TPP-Cu@HMS can specifically target mitochondria and in situ generate 1 O 2 against cancer cells. Specifically, to overcome the short lifespan of 1 O 2 , the released Cu 2+ ions from TPP-Cu@HMS could act as a Fentonlike agent to convert endogenous H 2 O 2 to $OH in the acidic environment of cancer cells, disrupt the mitochondrial membrane potential and lead to mitochondrial disintegration, which could systematically enhance the therapeutic efficiency of SDT. Therefore, we highlight the current strategy as a promising prospect for cancer therapy.
Introduction
Mitochondria as cellular power components play an important part in cell energy metabolism and survival in response to external stresses such as nutrient deprivation, ischemia and genotoxic agents. [1] [2] [3] [4] Damaged mitochondria can also induce a mitochondrial membrane potential change and subsequently cause mitochondria swelling/disintegration, cytochrome c and pro-apoptotic protein release, and eventually induce cell apoptosis/death. 5, 6 To control mitochondria-specic damage, stimuli-responsive probes and smart nanocarrier systems have been designed recently, which are sensitive to endogenous (pH, redox chemistry and enzymes) and exogenous stimuli (NIR lasers and magnetic eld). [7] [8] [9] [10] [11] [12] [13] Among the various stimuli, ultrasound (mechanical waves with a high penetrative power) as a new exogenous stimulus not only penetrates the depth of tumor tissues but also minimizes the side effects on the surrounding normal tissues. 14 Moreover, ultrasound sonodynamic therapy (SDT) as a promising non-invasive approach results in apoptosis in a variety of cancer cells including lymphocytes, myeloid leukemia and sarcoma cells through the activation of SDT agents to generate reactive oxygen species (ROS), cavitation, gas bubbles and hyperthermia. Especially in mitochondria-specic damage, ROS ( 1 O 2 , $OH, etc.) can lead to cell apoptosis/death efficiently. 15 Nevertheless, the heterogeneity of TME can set several biological barriers for SDT, such as lower pH and hypoxia conditions, which are attributed to the disorganized vasculature inside tumors and the anaerobic respiration of tumor cells, [16] [17] [18] increasing the risk of tumor relapse aer SDT.
Recently, Fenton-like agent (such as Cu 2+ , Mn 2+ , and Fe 2+ )based chemodynamic therapy (CDT) has been demonstrated for cancer therapy via the generation of $OH from endogenous H 2 O 2 in the most important physiological buffers to effectively induce DNA, protein and lipid damage, subsequently leading to cell apoptosis. [18] [19] [20] [21] Noteworthily, CDT is an oxygen-independent therapy that can overcome the hypoxia in TME and be easily combined with other therapeutic approaches such as PTT for enhanced cancer therapy according to our previous works. 19, 21 In this study, we introduced a new strategy combining SDT and CDT for the mitochondria-specic therapy of cancer cells (Scheme 1). To achieve this goal, we used the FDA-approved SDT agent hematoporphyrin monomethyl ether (HMME) to covalently conjugate with triphenylphosphonium (TPP)-modied mesoporous silica as the SDT nanoagent (TPP@HMS) and subsequently coordinated it with Cu 2+ (denoted as TPP-Cu@HMS) for the in situ generation of 1 O 2 and $OH in mitochondria upon H 2 O 2 /US for SDT-CDT.
Experimental

Materials
Mesoporous silica (MS) with an average diameter of 71 AE 2.1 nm and pore diameter of 13.3 nm, triphenylphosphonium (TPP-COOH) and succinimidyl propionic acid PEG (NHS-mPEG) were purchased from Xi'an Ruixi Company. N-Hydroxysuccinimide (NHS), hematoporphyrin monomethyl ether (HMME), N-(3-dimethylamino-propyl)-N-ethylcarbodiimide hydrochloride (EDC) and CuCl 2 were obtained from J&K Scien-tic. The Cell Counting Kit (CCK-8) and LIVE/DEAD Viability/ Cytotoxicity Kit were obtained from Dojindo China Co., Ltd. 3-Aminopropyltrimethoxysilane (APTES) and 2,7-dichlorodihy-drouoresceindiacetate (DCFH-DA) were purchased from Sigma-Aldrich. Deionized water with a resistivity of 18.2 MU cm was obtained from a Milli-Q Gradient System (Millipore, Bedford, MA, U.S.).
Cell culture
The liver cancer cells line (HepG2 cells) was obtained from ATCC (Manassas, VA). The cells were cultured in RPMI 1640 medium (contained 10% FBS) and penicillin-streptomycin (100 IU mL À1 , Cellgro, Manassas, VA) at 37 C in a humidied incubator containing 5% CO 2 .
Synthesis of the TPP-Cu@HMS
Initially, 10 mg of MS in ethanol was mixed with APTES (50 mL) under reux for 24 h. Aerwards, MS-NH 2 was centrifuged and 1 mg of HMME and 2 mg of TPP-COOH were added to the above mixture solution containing EDC/NHS (10 mg mL À1 ) for 24 h. Then, the resulting products TPP@HMS was centrifuged and washed 3 times with ethanol. Aerwards, TPP@HMS was mixed with NHS-mPEG for 24 h, and puried by centrifugation, and washed 3 times with DI water. The dose of HMME in TPP@HMS was calculated by subtracting the absorbance at 400 nm of HMME from its standard curve for concentrations ranging from 1-14 mg mL À1 (y ¼ 0.141x + 0.118, R 2 ¼ 0.996). Aer that, the TPP@HMS solution was mixed with CuCl 2 (pH 7.4, 10 mg mL À1 ) and stirred for 12 h. The nal product of TPP-Cu@HMS was obtained by centrifugation, and it was stored at 4 C for further use.
Characterization of TPP-Cu@HMS
Scanning transmission electron microscopy (STEM) with highangle annular dark-eld and transmission electron microscopy (TEM) were conducted on a JEM-2010 electron microscope (JEOL, Japan). UV-vis spectra of TPP@HMS were investigated using a Spectro Max M5e (Germany). Fluorescence spectra were measured using an Agilent Cary Eclipse uorescence spectrophotometer (Santa Clara, USA).
The intracellular location of TPP@HMS
To evaluate the subcellular location of TPP@HMS, HepG2 cells were rst seeded in 35 mm glass bottom Petri dishes with 5 Â 10 4 cells at 37 C in a 5% CO 2 atmosphere for 24 h incubation. Then, HepG2 cells containing TPP@HMS were coincubated for 6 h, and washed with PBS solution (pH 7.4) to remove the free TPP@HMS. Aerwards, the treated cells were co-stained with MitoTracker Red (500 nM) for 15 min and washed with PBS buffer solution. Subsequently, the cells were imaged via CLSM at 405 nm for HMME (TPP@HMS) and 561 nm for MitoTracker Red. Moreover, to investigate the morphology and mitochondrial membrane potential, the cells were then treated with or without US (0.75 W cm À2 , 1 WHz) for 3 min and then treated with the JC-1 dye detector kit according to the commercial protocol, and real-time imaged by CLSM.
The intracellular ROS generation and cytotoxicity of TPP-Cu@HMS
The ROS generation by TPP-Cu@HMS with or without US treatment was detected using DCFH-DA as the ROS indicator. Firstly, HepG2 cells were seeded in a 96-well plate with a density of 1 Â 10 5 per well and co-incubated a humid atmosphere containing 5% CO 2 for 24 h. Then, the above medium was refreshed with a new culture including TPP-Cu@HMS and co-incubated for 6 h. Next, the cancer cells were treated with ROS detector (100 mM, DCFH-DA) for 30 min. Subsequently, the cells were washed with PBS buffer and then treated with or without US (0.75 W cm À2 , 1 WHz) for 3 min, and imaged by CLSM. To evaluate the SDT killing effects of TPP-Cu@HMS, HepG2 cells were seeded into 35 mm glass bottom Petri dishes at a density of 5 Â 10 4 cells at 37 C in a 5% CO 2 atmosphere for 24 h. Then, the HepG2 cells were coincubated with TPP@HMS for 6 h, then washed with PBS buffer (pH 7.4) to remove the free TPP@HMS, and nally treated with 1 WHz US (0.75 W cm À2 , 1 WHz) for 3 min. The treated cells were stained by propidium iodide (PI) and imaged using a uorescence microscope. Next, to quantitative measure the cytotoxicity of TPP@HMS upon US treatment, the CCK8 assay was performed according to our previously published protocols. [18] [19] [20] [21] 
Statistical analysis
Statistical analysis of CCK8 data was investigated through the two-tailed paired Student's t-test or one-way of variance (ANOVA) protocol, where *p < 0.05, **p < 0.01, ***p < 0.001. The data is presented as the mean AE SD from at least three experiments.
Results and discussion
Hemoporn® is a commonly used PDT agent due to its satisfactory optical properties and ROS quantum yield (approximately 0.6). 21 However, the metabolism of hydrophilic Hemoporn® in clinic is very fast in the body, and thus it always suffers from a short retention time in tumors. 21, 22 In this study, we chose the hydrophobic HMME to covalently conjugate with MS as a new SDT nanoagent and decorated mPEG for enhancement in its circulation half-time. Firstly, the obtained MS with an average diameter of 71 AE 2.1 nm and pore diameter of 13.3 nm was modied with 3-aminopropyltrimethoxysilane (APTES) to gain the amino (-NH 2 ) group on the surface of MS. The morphology of MS-NH 2 was evaluated via transmission electron microscopy (TEM). As shown in Fig. 1A and the inset picture, MS-NH 2 showed good monodispersity and a spherical shape, with an average diameter of 71 AE 6.1 nm. Aer modication with APTES, HMME was then covalently conjugated to MS-NH 2 via the amido bond to form a new SDT agent (named HMS). Aerwards, the mitochondria-specic ligand of TPP-COOH and NHS-mPEG were conjugated with the surface of HMS through amido bonds (refer to TPP@HMS). The TEM image of TPP@HMS showed the typical spherical shape and the average diameter of 76 AE 6.9 nm (Fig. 1B) . The UV-vis-NIR spectrum obtained on a Spectro-Max M5e was further investigated to conrm the components of the nal product. As shown in Fig. 1C , four distinct peaks in the wavelength range of 450-750 nm at 506 nm, 544 nm, 576 nm and 622 nm (Qband) were observed clearly compared to MS-NH 2 without HMME conjugation, and the results are consistent with the typical absorption peaks of HMME. 22 The emission spectrum of TPP@HMS demonstrates that its uorescence emission is long in the NIR range (600 to 700 nm) (excited by 391 nm). To further conrm its components, STEM with high-angle annular dark-eld was performed. The nal data suggests the presence of N, O, C and Si homogenously distributed throughout TPP@HMS (Fig. 1E ).
Mitochondria-specic damage of cancer cells is an effective strategy with remarkable therapeutic potency in cancer therapy. [1] [2] [3] [4] To investigate the mitochondrial targeting ability of HMS with decoration of TPP-COOH, HepG2 cells as a typical cancer cell model were chosen. As shown in Fig. 2A and B , the confocal laser scanning microscopy (CLSM) images showed good overlap between TPP@HMS with red uorescence and MitoTracker Red with green uorescence (pseudo-color) aer co-incubation for 6 h, and Pearson's correlation coefficient (PCCs) was calculated to be 0.86 using the ImageJ soware. PBS-treated HepG2 cells stained with MitoTracker Red were as a control. To achieve excellent therapeutic efficiency for the treatment of cancer, in situ mitochondria ROS generation is a very promising approach. 5, 6 Inspired by this, we checked the 1 O 2 generation ability of our prepared TPP@HMS. The 1 O 2 indicator 1,3-diphenylisobenzofuran (DPBF) was used to measure 1 O 2 upon 1 WHz US (1 W cm À2 ). 24 The change in optical density was investigated by monitoring the US-vis spectrum. As shown in Fig. 3A and B , the absorbance of the DPBF solution containing TPP@HMS ranging from 350 to 500 nm signicantly decreased aer US, and the decrease was time dependent, suggesting the excellent 1 O 2 generation ability of TPP@HMS. In contrast, the DPBF solution without TPP@HMS did not obviously change under the same US power condition ( Fig. 3B and C) . Moreover, the mitochondrial morphology of the cancer cells was also examined by CLSM aer TPP@HMS treatment upon US (1 WHz, 0.75 W cm À2 ) for 3 min. As shown in Fig. 3D , obvious mitochondrial swelling/ disintegration was detected in the TPP@HMS-treated HepG2 cells aer US treatment compared to the control. Furthermore, the intracellular ROS were investigated using the green uorescence indicator 2,7-dichlorodihydrouorescein diacetate (DCFH-DA) (Fig. 3E) . [20] [21] [22] Green uorescence with a much higher uorescence intensity was obviously detected in TPP@HMS-treated HepG2 cells aer US treatment compared to the PBS-treated cells. These results suggested that our prepared TPP@HMS could act as an active mitochondria-specic SDT nanoagent for further treatment of cancer cells.
In the TME, hypoxia and acidic pH play an important role in the heterogeneity of tumors. 24 The limited oxygen in the TME can diminish the SDT effect, which may cause tumor relapse aer SDT treatment. In this study, we combined a Fenton-like agent as an oxygen-independent CDT approach to convert the H 2 O 2 in the TME into $OH to induce tumor cells apoptosis/necrosis and SDT, overcoming the above limitation for enhanced SDT efficiency. Cu 2+ ions as a Fenton-like agent have been widely used in CDT therapy. 19, 20, 25 To enhance the Cu 2+ ion accumulation in tumors, the oral administration of Cu 2+ -containing compounds is a currently available approach that is commonly utilized in copper deciency in clinic. Unfortunately, the systemic administration of Cu 2+ compounds may induce heavy-metal poisoning. 26, 27 Herein, Cu 2+ was coordinated with TPP@HMS via the NH 2 -medium coordination effect to form TPP-Cu@HMS at neutral pH according to our previously reported work. 28 STEM-HAADF was performed to conrm the existence of Cu in TPP-Cu@HMS. Fig. 4A shows the presence of Cu, N, Si, O, and C elements in TPP-Cu@HMS, and Cu was homogenously distributed throughout TPP-Cu@HMS, indicating the existence of Cu 2+ . Next, the bio-stability of TPP-Cu@HMS in physiological conditions (at pH 7.4) was investigated. The results showed 13.5% of Cu 2+ was released from TPP-Cu@HMS aer 24 h incubation, indicating its relative These results are similar to the intracellular $OH generation from TPP-Cu@HMS without US (Fig. S2 †) . Thus, the results indicate that TPP-Cu@HMS can act as an activatable SDT-CDT nanoagent for further cancer therapy. The mitochondrial membrane permeability (MMP) is essential in mitochondria apoptosis and cell death. Encouraged by the above results, we investigated the mitochondrial membrane (Dj m ) using the JC-1 dye detection kit (the potential sensitive indicator) and imaging by CLSM. As illustrated in Fig. 5 , the JC-1 monomers with green uorescence were more obviously and increased in the TPP-Cu@HMS-treated HepG2 cells aer 1 WHz US (0.75 W cm À2 ) for 3 min. The ratio of JC-1 aggregates with red uorescence/JC-1 monomers with green uorescence was reduced, indicating the high in situ ROS ( 1 O 2 and $OH) generation and accurate photodamage on mitochondria.
However, the JC-1 monomer uorescence intensity was low in the TPP-Cu@HMS-treated HepG2 cells alone. In contrast, the HepG2 cells without any treatment showed overwhelming red uorescence. Noteworthily, green uorescence was observed in the US-treated HepG2 cells in the absence of TPP-Cu@HMS mainly due to the cavitation effect of ultrasound. 22, 23 Next, the synergistic therapeutic efficiency of TPP-Cu@HMS was investigated by PI dead staining and analyzed through uorescence microscopy. A signicant amount of dead cells with red uorescence was obviously detected in the TPP-Cu@HMS-treated HepG2 cells aer received 1 WHz US (0.75 W cm À2 ) for 3 min compared to the TPP-Cu@HMStreated cells alone and US alone (Fig. 6A) . Meanwhile, to quantify the TPP-Cu@HMS cytotoxicity aer US treatment, Cell Counting Kit-8 assay (CCK-8) was performed. As illustrated in Fig. 6B , the cell viability of the TPP@HMS-treated cancer cells alone showed no obvious cytotoxicity aer 24 h incubation, and the mortality rate was very low even with the concentration of TPP@HMS up to 0.3 mg mL À1 , indicating that our prepared TPP@HMS has good biocompatibility. In contrast, the viable cells of TPP-Cu@HMS-treated HepG2 cells upon 1 WHz US (0.75 W cm À2 ) for 3 min signicantly decreased to 56.6%, suggesting the synergistic treatment of TPP-Cu@HMS compared to TPP-Cu@HMS-treated HepG2 cells alone without US treatment and HMS-treated HepG2 cells with US treatment. Overall, the results highlight the potential of our prepared TPP-Cu@HMS as a powerful therapeutic agent for enhanced mitochondria-specic cancer therapy. 
